Published : 17 Dec 2013

---

Bangalore, India and Freising, Germany, December 17, 2013 

Pieris AG, a next generation therapeutic protein R&D Company, and Stelis Biopharma, a subsidiary of Bangalore-based Strides Arcolab Ltd, had entered into a long-term agreement for worldwide development and commercialisation of a protein molecule- Anticalin®, primarily focused on ophthalmology.

As per the agreement, Pieris will take care of early stages of development in each collaborative programme using a novel Anticalin-based protein, while Stelis will be responsible for advancing the molecule through a first-in-human clinical study and drug manufacturing, the company said in a statement.

The collaboration will see the merger of Pieris' innovative drug discovery and early development capabilities with Stelis' strong bio-manufacturing and clinical development expertise.

 

Dinesh Jain, Founder CEO of Aagami, Inc., who supported Pieris in this deal, said "This deal yet again is the testimony of capabilities available for innovative Biotech work in India and signifies how global companies can benefit by partnering with large Indian MNCs – a viewpoint that Aagami has always promoted'".

For more information, please visit: http://www.pieris-ag.com/news-events/news-events-recent-news-2013-1216.php